Programs
Description
DISCOVERY
IND ENABLING
PHASE 1
Phase 2
PHASE 3
Bretisilocin (GM-2505): Short-Acting
5-HT2AR Agonist
Rapid-acting, 2 hour treatment duration
Indication: Depression
Non-hallucinogenic neuroplastogen
Indications: Depression, Anxiety
Improved Cardiac Safety Profile, Improved Efficacy
Indications: Opioid Use Disorder, PTSD, TBI
Single oral agent with reduced peripheral side effects
Indication: Schizophrenia
Orally Bioavailable, Rapid-acting, Low Dissociation, Potential At-Home Use
Indication: Depression
Neuroplastogens (partnered with AbbVie)
Blixeprodil (GM-1020): NMDAR Antagonist
GM-3009: Safer Ibogaine Analog
M1/M4 agonist
Program
GM-1020: Oral NMDAR Antagonist
Description
Orally Bioavailable, Rapid-acting, Low Dissociation, Potential At-Home Use
Indications: Depression, Bipolar Depression and Others
Phase
Discovery|IND| Phase 1| Phase 2
Program
GM-2505: Short Acting 5-HT2A Agonist
Description
60-90 minute duration
Indications: Depression, Anxiety and Others
Phase
Discovery|IND| Phase 1| Phase 2
Program
GM-5022: Oral Neuroplastogen (partnered with AbbVie)
Description
Non-hallucinogenic neuroplastogen
Indications: Depression, Anxiety and Others
Phase
Discovery| Pre-Clinical | IND | Phase 1
Program
GM-3009: Safer Ibogaine Analogs
Description
Improved Cardiac Safety Profile, Improved Efficacy
Indications: Opioid Use Disorder, PTSD, TBI
Phase
Discovery| Pre-Clinical | IND | Phase 1
Program
M1/M4 Agonist
Description
Oral, daily, reduced peripheral side effects
Indications: Schizophrenia
Phase
Discovery | Pre-Clinical | IND | Phase 1
